Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

Karim Fizazi,Neal D. Shore,Teuvo L.J. Tammela,Albertas Ulys,Egils Vjaters,Sergey Polyakov,Mindaugas Jievaltas,Murilo Luz,Boris Alekseev,Iris Kuss,Marie-Aude Le Berre,Oana Petrenciuc,Amir Snapir,Toni Sarapohja,Matthew R. Smith,Aramis Investigators

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

2020

Karim Fizazi
Neal D. Shore
Teuvo L.J. Tammela
Albertas Ulys
Egils Vjaters
Sergey Polyakov
Mindaugas Jievaltas
Murilo Luz
Boris Alekseev
Iris Kuss
Marie-Aude Le Berre
Oana Petrenciuc
Amir Snapir
Toni Sarapohja
Matthew R. Smith
Aramis Investigators

Abstract Background Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned pri...

Keywords:

castration resistant
Darolutamide
MEDLINE
Internal medicine
Anesthesiology
intensive care
Oncology
Medicine
Prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations